The promise of protein-based and gene-based clinical markers in heart transplantation: from bench to bedside
Mandeep R Mehra*, Erika Feller and Steve Rosenberg
Correspondence *Division of Cardiology, Room S3B06, University of Maryland School of Medicine, 22 South Greene Street, Baltimore, MD 21201, USA
Email mmehra@medicine.umaryland.edu
The main surveillance method for allograft rejection after heart transplantation is endomyocardial biopsy, but this method's invasive nature and poor uniformity of results pose problems. Noninvasive, reliable monitoring methods are, therefore, sought. In this review, protein-based and gene-based targets for the testing of allograft function to fulfill this role are discussed.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
A rendezvous before rejection: Where do T cells meet transplant antigens?Nature Medicine News and Views (01 Mar 2002)
RESEARCH
Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotideNature Medicine Article (01 Aug 1997)
Non-hematopoietic allograft cells directly activate CD8 + T cells and trigger acute rejection: An alternative mechanism of allorecognitionNature Medicine Article (01 Mar 2002)
See all 4 matches for Research